In this context, we decided to explore the expression of Plasmodium vaccine antigens fused to the granule bound starch synthase, the major protein associated to the starch matrix in all starch accumulating plants and algae. Starch-bound proteins are known to remain stable for years within the polysaccharide matrix purified from plants and algae. Starch can be easily purified from plants and algae by straightforward sedimentation procedures that in some systems do not even require centrifugation. In addition, cereal starch, with its role in human and animal diets, represents an approved source for the production of glucose for injection in humans. As a first approach to the use of recombinant polysaccharide particles for vaccine production, we focussed our efforts on the production of transgenic starch from chloroplasts of the green algae XAV939 customer reviews Chlamydomonas reinhardtii. We chose this system because of the ease and unparalleled speed with which constructs can be introduced and proteins expressed and correctly targeted to the chloroplast and polysaccharide granule. In addition, expression of recombinant vaccine antigens into starch granules localized into the Chlamydomonas chloroplasts would avoid protein N-glycosylation, a posttranslational modification that seems to be generally absent in Plasmodium falciparum. Moreover, starch metabolism has been investigated in great detail in this system through genetic dissection of mutants allowing optimization of starch granule protein content and polysaccharide structure. To evaluate this novel system, we have chosen two well-studied Plasmodium vaccine candidates, MSP1 and AMA1, which are thought to be involved in invasion of human red blood cells. The biosynthesis, purification, characterization, and immunologic properties of starch-stored clinically relevant antigens produced in Chlamydomonas reinhardtii chloroplast are described. Endometrial cancer is the most common gynecologic malignancy in developed countries, including an estimated 42,160 new cases in the United States in 2009 and claiming almost 7,780 lives. Based on clinico-pathologic and molecular data, endometrial adenocarcinomas are dichotomized into two types: type I, endometrioid adenocarcinoma and mucinous adenocarcinoma; type II, uterine serous carcinoma and clear cell carcinoma . EACs are the most frequent subtype and account for more than 80% of all endometrial adenocarcinomas. They are associated with obesity, exogenous hormonal therapy and they tend to present as low grade, early stage tumors with good outcomes, often cured with surgery alone. However, approximately 11% to 16% of women with EAC will present with FIGO stage II, III and stage IV disease with 5-year survival rate of 70%, 40–50% and 15–20% respectively. USCs account for 3– 10% of endometrial carcinomas. While USCs represent a minority of total endometrial cancer cases they are responsible for a disproportionate number of deaths.